In addition, ITGA7 may facilitate the stemness of cancer cells and development of drug resistance; hence, results in poor treatment response and high recurrence, which contributes to unfavorable survival profiles in NSCLC patients.23 And this was consistent with a previous study showing that ITGA7 is negatively correlated with survival profiles in glioblastoma patients as well.8 However, the number of NSCLC patients in this study was relatively small, thus a larger sample size was needed to further validate our findings. The gene discussed is ITGA7; the disease is glioblastoma.